The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia

Medical Oncology

Volumn 32, Issue 3, 2015, Pages

  Bilir, Cemil ^a   Engin, Huseyin ^a   Can, Murat ^a   Temi, Yasemin Bakkal ^a   Demirtas, Derya ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Cachexia; Hormones; Inflammation; Survival; TRAF 6

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; GALANIN; HORMONE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; NEUROPEPTIDE Y; OREXIN A; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; SERUM ALBUMIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY MASS; BREAST CANCER; CACHEXIA; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY FUNCTION TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LARYNX CANCER; LIVER FUNCTION TEST; LUNG CANCER; MALE; METASTASIS; MIDDLE AGED; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; STOMACH CANCER; TESTOSTERONE BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; COMPLICATION; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; PROGNOSIS;

BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CACHEXIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; SERUM ALBUMIN; TESTOSTERONE; TNF RECEPTOR-ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922126731     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0497-y     Document Type: Article

References (18)

1. Wanger T, Foster NR, Nguyen PL, Jatoi A. Patients’ rationale for declining participation in a cancer-associated weight loss study. J Cachexia Sarcopenia Muscle. 2014;5:121–5.
2. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Nutritional deterioration in cancer: the role of disease and diet. Clin Oncol. 2003;15:443–50.
3. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980;69:491–7.
4. Ikeda T, Nishiguchi Y, Chung Y, Yamada N, Sowa M. Experimental study of the effect of IL-6 on cancer cachexia. Oncol Rep. 1997;4:921–6.
5. Tan BH, Deans DA, Skipworth RJ, Ross JA, Fearon KC. Biomarkers for cancer cachexia: is there also a genetic component to cachexia? Support Care Cancer. 2008;16:229–34.
6. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–4.
7. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995;75:2077–782.
8. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–77.
9. McMillan DC, Watson WS, O’Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39:210–3.
10. Gupta D, Lis GC. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.
11. Plewka A, Madej P, Plewka D, et al. The TRAF2 and TRAF6 expression in myomas and myometrium of women in reproduction and perimenopausal age. Folia Histochem Cytobiol. 2010;48:407–16.
12. Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Annu Rev Nutr. 2006;26:435–61.
13. Sun YS, Ye ZY, Qian ZY, Xu XD, Hu JF. Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J Exp Clin Cancer Res. 2012;31:8.
14. Paul PK, Gupta SK, Bhatnagar S, et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J Cell Biol. 2010;191:1395–411.
15. Cağlar K, Kutluk T, Varan A, et al. Leptin and neuropeptide Y plasma levels in children with cancer. J Pediatr Endocrinol Metab. 2005;18:485–9.
16. Kowalczuk A, Wiecek A, Franek E, Kokot F. Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy. Pol Arch Med Wewn. 2001;106:657–68.
17. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411–25.
18. Gu L, Dai L, Cao C, et al. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention. PLoS One. 2013;8:e57436.